Recommended

New webinar: The path to optimisation in pharmaceutical microbiology
New webinar in 2025: Trends for life sciences quality leaders in 2025 – mastering what matters! Register your details now to secure your place!
New upcoming webinar: Navigating pharmaceutical environmental monitoring in a changing industry! Register your details today!
Explore our new Pharma Horizons: Sustainability report for key developments in the pharmaceutical industry!
Discover more in our new application note: validating recombinant cascade reagents in 3 simple steps
reference

Patient adherence: the true costs

References for ‘Patient adherence: the true costs’, in European Pharmaceutical Review Issue 3 2020.

References

  1. DiMatteo MR. Social support and patient adherence to medical treatment: A meta-analysis. Health Psychol. 23, 2004, 207-218.
  2. Chesney MA. Factors affecting adherence to antiretroviral therapy. Infect. Dis., 30(S2) 2000 S171-176.
  3. Martin LR, Williams SL, Haskard KB, DiMatteo MR. The challenge of patient adherence. Ther Clin Risk Manag., 1(3), 2005,189–199.
  4. Sutton SS, Magagnoli J, Hardin JW. Impact of Pill Burden on Adherence, Risk of Hospitalization, and Viral Suppression in Patients With HIV Infection and AIDS Receiving Antiretroviral Therapy. Pharmacotherapy, 36(4), 2016a,385-401.
  5. Srivastava K, Arora A, Kataria A, Cappelleri JC, et al. Impact of reducing dosing frequency on adherence to oral therapies: a literature review and meta-analysis. Patient Prefer Adherence. 7, 2013, 419–434.
  6. Ming RT, Teo V, Yu HK, Raaj S, et al. Association between number of doses per day, number of medications and patient’s non-compliance, and frequency of readmissions in a multi-ethnic Asian population. Preventive Med. Rep., 1, 2014, 43-47.
  7. Elder DP, Kuentz M, Holm R. Antibiotic Resistance: The Need For a Global Strategy. Pharm. Sci., 105, 2016, 2278-2287.
  8. Hay M, Thomas DW, Craighead JL, Economides C, et al. Clinical development success rates for investigational drugs. Biotechnol., 32, 2014, 40-51.
  9. Cutler RL, Fernandez-Llimos F, Frommer M, Benrimoj C, et al. Economic impact of medication nonadherence by disease groups: a systematic review. BMJ Open 2018;8:e016982. doi:10.1136/bmjopen-2017-016982. Accessed 05 June 2020.
  10. Currie CJ, Peyrot M, Morgan CL, Poole CD, et al. The Impact of Treatment Noncompliance on Mortality in People with Type 2 Diabetes. Diabetes Care, 35(6), 2012, 1279–1284.
  11. Satsoglou S, Tziomalos K. Fixed‐dose combinations: A valuable tool to improve adherence to antihypertensive treatment. Clin. Hypertens., 20, 2018, 908–909.
  12. Lancet editorial. Treatment adherence: Can fixed dose combinations help? P91, 3(2), Lancet Diabetes & Endrocrinology, 1-2. DOI:https://doi.org/10.1016/S2213-8587(15)70011-2.
  13. Sutton SS, Hardin JW, Bramley TJ, D’Souza AO, et al. Single- Versus Multiple-Tablet HIV Regimens: Adherence and Hospitalization Risks. J. Manag. Care, 22(4), 2016b,242-8.
  14. EMC website. Triumeq 50 mg/600 mg/300 mg film-coated tablets. https://www.medicines.org.uk/emc/product/3318. Accessed on 06 June 2020.
  15. Siew A. Tackling challenges in the development of fixed dose combinations. Tech., 38(4), 2014, 1-2.
  16. Kanasty R, Low S, Bhise N, Yang J, et al. A pharmaceutical answer to nonadherence: Once weekly oral memantine for Alzheimer’s disease. Contr. Release, 303, 2019, 34-41.
  17. Wright JC, Burgess DJ (Eds.) Long Acting Injections and Implants, CRS Press, 2012.pp.1-557.